Cytek Biosciences (CTKB) Operating Income (2020 - 2026)

Cytek Biosciences (CTKB) has 7 years of Operating Income data on file, last reported at -$18.5 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Income fell 23.29% year-over-year to -$18.5 million; the trailing twelve-month figure through Mar 2026 stood at -$43.9 million (down 77.16% YoY), and the FY2025 full-year result was -$40.4 million, down 96.77% from the prior year.
• Operating Income for Q1 2026 stood at -$18.5 million, down from -$5.6 million in the prior quarter.
• Across five years, Operating Income topped out at $3.0 million in Q4 2024 and bottomed at -$18.5 million in Q1 2026.
• The 5-year median for Operating Income is -$6.4 million (2023), against an average of -$6.4 million.
• The widest annual swing landed in 2023, when Operating Income tumbled 924.35%; it then surged 2279.56% in 2024.
• A 5-year view of Operating Income shows it stood at $84000.0 in 2022, then slumped by 263.1% to -$137000.0 in 2023, then soared by 2279.56% to $3.0 million in 2024, then sank by 287.34% to -$5.6 million in 2025, then slumped by 230.05% to -$18.5 million in 2026.
• The last three Operating Income figures came in at -$18.5 million (Q1 2026), -$5.6 million (Q4 2025), and -$9.2 million (Q3 2025), per Business Quant data.

Peer Comparison